335 related articles for article (PubMed ID: 26059438)
1. Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer.
Braig F; März M; Schieferdecker A; Schulte A; Voigt M; Stein A; Grob T; Alawi M; Indenbirken D; Kriegs M; Engel E; Vanhoefer U; Grundhoff A; Loges S; Riecken K; Fehse B; Bokemeyer C; Binder M
Oncotarget; 2015 May; 6(14):12035-47. PubMed ID: 26059438
[TBL] [Abstract][Full Text] [Related]
2. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
3. New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
Bronte G; Silvestris N; Castiglia M; Galvano A; Passiglia F; Sortino G; Cicero G; Rolfo C; Peeters M; Bazan V; Fanale D; Giordano A; Russo A
Oncotarget; 2015 Sep; 6(28):24780-96. PubMed ID: 26318427
[TBL] [Abstract][Full Text] [Related]
4. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
Sartore-Bianchi A; Martini M; Molinari F; Veronese S; Nichelatti M; Artale S; Di Nicolantonio F; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
Cancer Res; 2009 Mar; 69(5):1851-7. PubMed ID: 19223544
[TBL] [Abstract][Full Text] [Related]
6. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.
Arena S; Siravegna G; Mussolin B; Kearns JD; Wolf BB; Misale S; Lazzari L; Bertotti A; Trusolino L; Adjei AA; Montagut C; Di Nicolantonio F; Nering R; Bardelli A
Sci Transl Med; 2016 Feb; 8(324):324ra14. PubMed ID: 26843189
[TBL] [Abstract][Full Text] [Related]
7. ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.
Geißler AL; Geißler M; Kottmann D; Lutz L; Fichter CD; Fritsch R; Weddeling B; Makowiec F; Werner M; Lassmann S
Oncotarget; 2017 Mar; 8(10):17164-17190. PubMed ID: 28199979
[TBL] [Abstract][Full Text] [Related]
8. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
9. The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
Sánchez-Martín FJ; Bellosillo B; Gelabert-Baldrich M; Dalmases A; Cañadas I; Vidal J; Martinez A; Argilés G; Siravegna G; Arena S; Koefoed K; Visa L; Arpí O; Horak ID; Iglesias M; Stroh C; Kragh M; Rovira A; Albanell J; Tabernero J; Bardelli A; Montagut C
Clin Cancer Res; 2016 Jul; 22(13):3260-7. PubMed ID: 26888827
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
[TBL] [Abstract][Full Text] [Related]
11. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
Fabian P; Berkovcová J
Cesk Patol; 2011 Oct; 47(4):154-8. PubMed ID: 22145213
[TBL] [Abstract][Full Text] [Related]
12. The genomic landscape of response to EGFR blockade in colorectal cancer.
Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE
Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
14. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
[TBL] [Abstract][Full Text] [Related]
15. Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy.
Price T; Ang A; Boedigheimer M; Kim TW; Li J; Cascinu S; Ruff P; Satya Suresh A; Thomas A; Tjulandin S; Peeters M
Cancer Biol Ther; 2020 Oct; 21(10):891-898. PubMed ID: 33026965
[TBL] [Abstract][Full Text] [Related]
16. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
Braig F; Voigtlaender M; Schieferdecker A; Busch CJ; Laban S; Grob T; Kriegs M; Knecht R; Bokemeyer C; Binder M
Oncotarget; 2016 Jul; 7(28):42988-42995. PubMed ID: 27119512
[TBL] [Abstract][Full Text] [Related]
17. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
Bardelli A; Siena S
J Clin Oncol; 2010 Mar; 28(7):1254-61. PubMed ID: 20100961
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab.
Mlcochova J; Faltejskova-Vychytilova P; Ferracin M; Zagatti B; Radova L; Svoboda M; Nemecek R; John S; Kiss I; Vyzula R; Negrini M; Slaby O
Oncotarget; 2015 Nov; 6(36):38695-704. PubMed ID: 26497852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
